New drug tested for patients whose immune systems attack their own blood
NCT ID NCT07083960
Summary
This early-stage trial is testing a new injectable drug called OM336 in adults whose immune systems mistakenly destroy their own red blood cells or platelets. The main goal is to check if the drug is safe and well-tolerated in people who have not fully responded to at least one prior treatment. Researchers will give the drug in increasing doses to small groups of participants to find a safe level.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icon Cancer Center South Brisbane
RECRUITINGBrisbane, Queensland, 4066, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Liverpool Hospital
RECRUITINGSydney, New South Wales, 2107, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Canberra Hospital
RECRUITINGCanberra, Australian Capital Territory, 2605, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.